V8 Peptides — Engineered Performance
Research Library
Tesamorelin + Ipamorelin Blend Explained: A Research Guide
TesamorelinIpamorelinBlend

Tesamorelin + Ipamorelin Blend Explained: A Research Guide

V8 Peptides Research TeamNovember 17, 2026

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer: A tesamorelin and ipamorelin blend combines a GHRH analog (tesamorelin) with a selective ghrelin-receptor agonist (ipamorelin) in one lyophilized vial, so that two separate receptor pathways can be studied together in preclinical and in-vitro models. It is a laboratory research product only. This explainer covers the two components, why researchers pair them, blend versus separate vials, and what a certificate of analysis should show for each peptide.

What is in the vial

A tesamorelin and ipamorelin blend puts two different peptides in one lyophilized vial. Tesamorelin is a 44-residue analog of growth hormone-releasing hormone (GHRH) that carries a trans-3-hexenoyl group on its N-terminus, a modification introduced to slow enzymatic breakdown. Ipamorelin is a five-residue synthetic peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as an agonist at the growth hormone secretagogue receptor, also called GHS-R1a or the ghrelin receptor. The two molecules are unrelated in sequence and bind different receptors, which is the entire reason anyone would put them together.

The blend is coming soon to the V8 catalog as the Tesamorelin + Ipamorelin Blend, planned in two fill ratios: 5 mg tesamorelin with 5 mg ipamorelin, and 12 mg tesamorelin with 3 mg ipamorelin. Both are intended for laboratory research only. This article explains the reasoning behind a two-component vial, how it compares with separate vials, and what a certificate of analysis for a blend should actually show.

Two receptors, two signals

In pituitary somatotroph models, growth hormone release is controlled by more than one input. GHRH binds the GHRH receptor, a G protein-coupled receptor that raises intracellular cAMP and also supports transcription of the growth hormone gene. Ghrelin and its synthetic mimetics bind GHS-R1a, which signals mainly through phospholipase C and calcium mobilization. Because the intracellular routes differ, the two signals can add up and, in published physiology work, sometimes exceed a simple sum. The paper by Veldhuis and Bowers listed in the references examines what determines GHRH and GH-releasing peptide synergy.

A third layer is the hypothalamic brake, somatostatin. Many in vitro and animal designs ask how the two receptor routes behave when somatostatin tone is present or absent. A GHRH analog alone engages one arm; a secretagogue alone engages the other. Using both lets a lab ask questions about the interaction itself rather than about either arm in isolation.

None of this is a statement about use in people. It is the mechanistic rationale that appears in preclinical and in-vitro designs.

Meet the two components

Tesamorelin

Tesamorelin is built on the full human GHRH(1-44) sequence with the N-terminal hexenoyl cap. That cap shields the peptide from dipeptidyl peptidase cleavage, which otherwise inactivates native GHRH within minutes in biological media. For a sequence-level walkthrough see the tesamorelin research overview and what is Tesa (tesamorelin). The single-compound vial is listed at /products/tesamorelin.

Ipamorelin

Ipamorelin was described in 1998 by Raun and colleagues as a highly selective secretagogue. In their in vitro and animal work it released growth hormone with potency comparable to GHRP-6 but, unlike older secretagogues, did not noticeably raise ACTH or cortisol readouts. That selectivity is the main reason it became a reference tool compound. See the ipamorelin research overview and ipamorelin versus GHRP-6. The single-compound vial is at /products/ipamorelin-10mg.

Ghrelin itself, the endogenous GHS-R1a ligand, was identified in 1999 as an acylated peptide from stomach tissue, which explains why this receptor class is also discussed in appetite and energy-balance research.

Why one vial instead of two

The practical case for a blend is convenience and consistency in experimental design. Whenever both peptides are required in the same assay, a single vial means one reconstitution event, one set of handling steps, one lot reference to record and fewer chances for pipetting variation between the two components.

The practical case for separate vials is flexibility. Fixed ratios cannot be changed after the powder is mixed. If a protocol needs to vary one peptide while holding the other constant, or wants a ratio that the blend does not offer, individual vials are the better tool. Separate vials also let a lab run single-agent control arms from the same lots.

FeatureBlend vialSeparate vials
Ratio controlFixed at manufacture (5:5 or 12:3 mg)Fully adjustable by the researcher
Handling stepsOne reconstitutionTwo reconstitutions
Single-agent controlsNeed separate vials anywayBuilt in
Lot recordsOne lot, two componentsTwo lots to track
Per-component COAMust report both peptidesOne report per vial

For a parallel discussion on a related pair, read CJC-1295 and ipamorelin blend versus separate vials. V8 already lists a related blend, the CJC-1295 (no DAC) + Ipamorelin Blend, which pairs a different GHRH analog with the same secretagogue.

Why the two ratios

The 5 mg / 5 mg fill is an equal-mass ratio. Because tesamorelin is a much larger molecule (roughly 5.1 kDa versus about 0.7 kDa for ipamorelin), equal mass means far fewer moles of tesamorelin than of ipamorelin. The 12 mg / 3 mg fill shifts the mass toward the GHRH analog and moves the molar ratio closer to parity. Which suits a given design depends on what the experiment is asking. Use the reconstitution calculator to convert vial contents into molar terms, and read the calculator guide for the method.

Handling a two-peptide lyophilized vial

Lyophilization removes water so that both peptides sit in a stable solid cake. General practice applies: keep sealed vials cold, dry and shielded from light, let a cold vial warm before opening, and log the date first opened. Background on the process is in what is lyophilization, and the stepwise method is in how to reconstitute a lyophilized peptide. For component-specific notes see tesamorelin storage. One extra consideration for a blend is that the two components may differ in stability after reconstitution, so the shorter-lived component sets the practical working window.

What to check on a blend COA

A single purity figure is not enough for a two-peptide vial. A report that lists only one HPLC number leaves open which peptide it describes. Use this checklist:

  • Both components named. The report should identify tesamorelin and ipamorelin separately, not just “blend.”
  • A chromatogram with two resolved main peaks. Each should be identifiable, with minor peaks visible and the integration shown. See understanding HPLC purity.
  • Per-component identity. Ask which method confirms each expected molecular weight, about 5.1 kDa for tesamorelin and about 0.7 kDa for ipamorelin. HPLC versus mass spectrometry explains why purity and identity are different questions.
  • Per-component fill amount that matches the label (for example 5 mg and 5 mg), and whether the figure is total powder or net peptide.
  • Lot reference and test date matching the vial, plus the testing laboratory name.

V8 sells its products for laboratory research use only and publishes certificates of analysis on /coa for tested lots. Always compare the report to the lot printed on your own vial. The general method is covered in how to read a COA, with compound-specific notes in tesamorelin purity testing and ipamorelin purity testing.

Common misunderstandings

“Tesamorelin and ipamorelin do the same thing.” They bind different receptors with different downstream signaling, which is exactly why they are paired.

“A blend is always better than two vials.” It is more convenient, but it removes ratio flexibility and does not replace single-agent controls.

“Equal mass means equal amounts.” The two peptides differ about sevenfold in molecular weight, so mass and moles diverge.

“Animal and cell data predict human outcomes.” They do not, and this article makes no such claim. Browse the wider V8 shop for other research compounds.

Frequently asked questions

What is a tesamorelin and ipamorelin blend?

A single lyophilized vial containing tesamorelin, a GHRH analog, and ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist, for laboratory research.

Is the blend available now?

Not yet. See the product page for current status.

Which ratios are planned?

Two fills: 5 mg tesamorelin with 5 mg ipamorelin, and 12 mg tesamorelin with 3 mg ipamorelin.

Why combine a GHRH analog with a secretagogue?

They act on separate receptors with different intracellular signaling, so researchers can study the interaction between the two pathways in preclinical models.

Is tesamorelin a peptide?

Yes. It is a 44-residue synthetic analog of GHRH with an N-terminal trans-3-hexenoyl modification.

What makes ipamorelin described as selective?

In early in vitro and animal work it released growth hormone without a noticeable rise in ACTH or cortisol readouts, unlike older secretagogues.

Can I change the ratio in a blend vial?

No. The ratio is fixed at manufacture. Separate vials are the option when a design needs adjustable ratios.

Why does equal mass not mean equal moles here?

Tesamorelin is roughly seven times heavier per molecule than ipamorelin, so equal milligrams contain far fewer tesamorelin molecules.

What should a blend COA show?

Both components named, a chromatogram with two resolved peaks, identity confirmation for each, per-component fill amounts, a lot reference and a test date.

Is this product for human use?

No. V8 Peptides sells it for laboratory research use only, not for human or animal consumption.

References

  1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822.
  2. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. PMID: 10604470.
  3. Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009;296(5):E1085-E1092. PMID: 19240251.

All V8 Peptides products are sold for laboratory research use only. They are not drugs, foods, or cosmetics and are not intended for human or animal consumption.

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.